Immunotherapeutic Approaches in TNBC: The Latest Data

Access Course

 

Immunotherapeutic Approaches in TNBC: The Latest DataDrs Emens and Adams discuss the emerging data for checkpoint inhibition in both the metastatic and neoadjuvant disease settings for TNBC.

 

This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

 

The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of TNBC.

 

Learning Objectives:

  • Have increased knowledge regarding the biologic rationale for using immune checkpoint inhibitors (ICIs) to manage patients with TNBC.
  • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs in the management of TNBC
  • Have increased knowledge regarding the ongoing clinical trials that may affect standards of care across the treatment continuum for TNBC

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Mar. 22, 2020 - Mar. 22, 2021

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Resources for Clinicans from SITC:

 

sitc-cig-rgb.png

 

 

 

View Available Guidelines Here.

Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.25
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.25